Cardioverter DefIbriIlator PlacEMent for priMary Prevention of Sudden cArdiac Death in Patients Older Than 70 Years
Cardioverter DefIbriIlator PlacEMent for priMary Prevention of Sudden cArdiac Death in Patients Older Than 70 Years: A Randomized Controlled Trial
Assistance Publique - Hôpitaux de Paris
730 participants
Jun 29, 2022
INTERVENTIONAL
Conditions
Summary
The primary objective of DILEMMA study is to assess whether the "heart failure optimal therapy alone (HFOT)" strategy is non inferior to the "HFOT+ICD" strategy in terms of overall survival 48 months after randomization, in patients ≥ 70 years with an ICD indication for primary prevention of SCD whether there is an indication for cardiac resynchronization therapy or not.
Eligibility
Inclusion Criteria6
- ≥70 years old,
- Left ventricular ejection fraction ≤ 35%
- NYHA class II or III
- Heart failure HFOT ≥ 3 months
- Providing informed consent
- Affiliated to a French Health Insurance system.
Exclusion Criteria10
- Enrolled in or planning to enroll in a conflicting interventional trial
- Prior unstable sustained ventricular arrhythmia requiring external cardioversion
- Myocardial infarction within the 40 days
- Coronary artery intervention (catheter or surgical) within 90 days
- History of syncope in the previous 6 months
- Advanced cerebrovascular disease
- Cognitive impairment leading to the incapacity of consent
- Any disease other than cardiac disease (e.g. cancer, uremia, liver failure), associated with a likelihood of survival less than 1 year.
- Patient under tutorship, curatorship, or legal safeguard
- Persons deprived of their liberty by judicial or administrative decision (prisoner)
Interventions
This group will undergo an ICD implantation (type and manufacturer at the discretion of the local investigator) in addition to heart failure medical therapy optimization. Patients of the "HFOT+ICD" group will be scheduled for ICD implantation.
Patients of the "HFOT alone" group will not undergo ICD implantation (except if they develop sustained ventricular arrhythmias and fulfil for secondary prevention ICD implantation), and continue with medical therapy optimization only.
Locations(19)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05373940